| Jacob Rinkinen, | |
|
3424 Ramada Dr, Highland, MI 48356-1870 | |
| (248) 240-1140 | |
| Not Available |
| Full Name | Jacob Rinkinen |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 9 Years |
| Location | 3424 Ramada Dr, Highland, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275929861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | ME157486 (Florida) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center - Jacksonville | Jacksonville, FL | Hospital |
| Baptist Medical Center Beaches | Jacksonville beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Florida Surgeons Pa | 2769381391 | 223 |
News Archive
Former Minn. Gov. Tim Pawlenty has vowed to bring back the term "Obamneycare" while Jon Huntsman, former Utah governor, ambassador to China and the latest to throw his hat into the GOP presidential nomination race, explained his position on the individual mandate.
Today's early morning highlights from the major news organizations, including more analysis of the Supreme Court's Hobby Lobby decision and concerns in New York about significant insurance rate increases for 2015.
About one in a hundred patients with apparently incurable non-small cell lung cancer (NSCLC) survive five or more years after being given relatively small doses of radiation therapy (RT) meant to ease symptoms, according to a new study.
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 7 days ago
| Entity Name | North Florida Surgeons Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912953290 PECOS PAC ID: 2769381391 Enrollment ID: O20040102000629 |
News Archive
Former Minn. Gov. Tim Pawlenty has vowed to bring back the term "Obamneycare" while Jon Huntsman, former Utah governor, ambassador to China and the latest to throw his hat into the GOP presidential nomination race, explained his position on the individual mandate.
Today's early morning highlights from the major news organizations, including more analysis of the Supreme Court's Hobby Lobby decision and concerns in New York about significant insurance rate increases for 2015.
About one in a hundred patients with apparently incurable non-small cell lung cancer (NSCLC) survive five or more years after being given relatively small doses of radiation therapy (RT) meant to ease symptoms, according to a new study.
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacob Rinkinen, 11945 San Jose Blvd, Ste 300, Jacksonville, FL 32223-1627 Ph: (904) 396-1725 | Jacob Rinkinen, 3424 Ramada Dr, Highland, MI 48356-1870 Ph: (248) 240-1140 |
News Archive
Former Minn. Gov. Tim Pawlenty has vowed to bring back the term "Obamneycare" while Jon Huntsman, former Utah governor, ambassador to China and the latest to throw his hat into the GOP presidential nomination race, explained his position on the individual mandate.
Today's early morning highlights from the major news organizations, including more analysis of the Supreme Court's Hobby Lobby decision and concerns in New York about significant insurance rate increases for 2015.
About one in a hundred patients with apparently incurable non-small cell lung cancer (NSCLC) survive five or more years after being given relatively small doses of radiation therapy (RT) meant to ease symptoms, according to a new study.
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 7 days ago